Cell Biotech Co. Ltd (049960) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cell Biotech Co. Ltd (049960) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.15 Billion ≈ $2.81 Million USD) by net assets (₩127.11 Billion ≈ $86.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cell Biotech Co. Ltd market capitalisation for the company's overall valuation and market capitalisation.
Cell Biotech Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Cell Biotech Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cell Biotech Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cell Biotech Co. Ltd ranked by their cash flow conversion efficiency. Explore how high is Cell Biotech Co. Ltd's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ybox Real Estate Ltd
TA:YBOX
|
-0.067x |
|
MediciNova Inc
NASDAQ:MNOV
|
-0.039x |
|
Hennessy Ad
NASDAQ:HNNA
|
0.023x |
|
Thryv Holdings Inc
NASDAQ:THRY
|
0.101x |
|
Columbus Acquisition Corp Ordinary Shares
NASDAQ:COLA
|
-0.002x |
|
Gopeng Bhd
KLSE:2135
|
-0.469x |
|
Kalleback Property Invest AB
ST:KAPIAB
|
0.049x |
|
Holland Colours NV
AS:HOLCO
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Cell Biotech Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Cell Biotech Co. Ltd from 2011 to 2024. View 049960 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩124.17 Billion ≈ $84.15 Million |
₩19.27 Billion ≈ $13.06 Million |
0.155x | +122.14% |
| 2023-12-31 | ₩111.89 Billion ≈ $75.82 Million |
₩7.82 Billion ≈ $5.30 Million |
0.070x | -41.08% |
| 2022-12-31 | ₩108.09 Billion ≈ $73.25 Million |
₩12.81 Billion ≈ $8.68 Million |
0.119x | -15.07% |
| 2021-12-31 | ₩106.69 Billion ≈ $72.30 Million |
₩14.89 Billion ≈ $10.09 Million |
0.140x | +45.93% |
| 2020-12-31 | ₩99.98 Billion ≈ $67.76 Million |
₩9.56 Billion ≈ $6.48 Million |
0.096x | -3.14% |
| 2019-12-31 | ₩103.60 Billion ≈ $70.21 Million |
₩10.23 Billion ≈ $6.93 Million |
0.099x | -25.37% |
| 2018-12-31 | ₩105.62 Billion ≈ $71.58 Million |
₩13.98 Billion ≈ $9.47 Million |
0.132x | -47.02% |
| 2017-12-31 | ₩90.20 Billion ≈ $61.12 Million |
₩22.53 Billion ≈ $15.27 Million |
0.250x | +16.83% |
| 2016-12-31 | ₩84.15 Billion ≈ $57.03 Million |
₩17.99 Billion ≈ $12.19 Million |
0.214x | -19.39% |
| 2015-12-31 | ₩68.76 Billion ≈ $46.60 Million |
₩18.24 Billion ≈ $12.36 Million |
0.265x | +40.17% |
| 2014-12-31 | ₩52.36 Billion ≈ $35.48 Million |
₩9.91 Billion ≈ $6.71 Million |
0.189x | -9.37% |
| 2013-12-31 | ₩43.05 Billion ≈ $29.17 Million |
₩8.99 Billion ≈ $6.09 Million |
0.209x | +23.25% |
| 2012-12-31 | ₩36.42 Billion ≈ $24.68 Million |
₩6.17 Billion ≈ $4.18 Million |
0.169x | -1.36% |
| 2011-12-31 | ₩31.77 Billion ≈ $21.53 Million |
₩5.45 Billion ≈ $3.70 Million |
0.172x | -- |
About Cell Biotech Co. Ltd
Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.